Skip to Main content Skip to Navigation
Journal articles

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT ‐0701 MAPS phase 3 trial

Elodie Maille 1, 2 Jérôme Levallet 1, 2 Fatéméh Dubois 3, 1, 2 Martine Antoine 4 Claire Danel 5 Christian Creveuil 1, 6 Julien Mazieres 7, 8 Jacques Margery 9, 10 Laurent Greillier 11, 12 Valérie Gounant 13, 14 Denis Moro‐sibilot 15 Olivier Molinier 16 Hervé Léna 17 Isabelle Monnet 16 Emmanuel Bergot 1, 6 Alexandra Langlais 18 Franck Morin 18 Arnaud Sherpereel 19, 20 Gérard Zalcman 21, 13, 5 Guénaëlle Levallet 3, 1, 2 
Abstract : The Hippo pathway effector YAP is dysregulated in malignant pleural mesothelioma (MPM). YAP’s target genes include the secreted growth factor amphiregulin (AREG), which is overexpressed in a wide range of epithelial cancers and plays an elusive role in MPM. We assayed the expression of YAP and AREG in MPM pathology samples and that of AREG additionally in plasma samples of patients from the randomized phase 3 IFCT-0701 Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) using immunohistochemistry and ELISA assays, respectively. MPM patients frequently presented high levels of tumor AREG (64.3%), a high cytosolic AREG expression being predictive of a better prognosis with longer median overall and progression-free survival. Surprisingly, tumor AREG cytosolic expression was not correlated with secreted plasma AREG. By investigating the AREG metabolism and function in MPM cell lines H2452, H2052, MSTO-211H, and H28, in comparison with the T47D ER+ breast cancer cell line used as a positive control, we confirm that AREG is important for cell invasion, growth without anchorage, proliferation, and apoptosis in mesothelioma cells. Yet, most of these MPM cell lines failed to correctly execute AREG post-translational processing by metalloprotease ADAM17/tumor necrosis factor-alpha-converting enzyme (TACE) and extra-cell secretion. The favorable prognostic value of high cytosolic AREG expression in MPM patients could therefore be sustained by default AREG post-translational processing and release. Thus, the determination of mesothelioma cell AREG content could be further investigated as a prognostic marker for MPM patients and used as a stratification factor in future clinical trials.
Document type :
Journal articles
Complete list of metadata

https://hal-normandie-univ.archives-ouvertes.fr/hal-03613510
Contributor : Carole Brunaud Connect in order to contact the contributor
Submitted on : Friday, March 18, 2022 - 3:07:34 PM
Last modification on : Sunday, June 26, 2022 - 1:27:34 AM
Long-term archiving on: : Sunday, June 19, 2022 - 7:04:56 PM

File

2022_Maille_Intl Journal of Ca...
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Elodie Maille, Jérôme Levallet, Fatéméh Dubois, Martine Antoine, Claire Danel, et al.. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT ‐0701 MAPS phase 3 trial. International Journal of Cancer, Wiley, 2022, 150 (11), pp.1889-1904. ⟨10.1002/ijc.33997⟩. ⟨hal-03613510⟩

Share

Metrics

Record views

30

Files downloads

63